RETROPHIN, INC. (NASDAQ:RTRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
RETROPHIN, INC. (NASDAQ:RTRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(d) As previously reported in the Current Report on Form 8-K filed by Retrophin, Inc. (the “Company”) on March 27, 2017>(the “Original 8-K”), the Company’s Board of Directors appointed John A. Orwin>as a director on March 23, 2017. At the time of the filing of the Original 8-K, it had not yet been determined on what committees Mr. Orwin>would serve. This amendment to the Original 8-K is being filed to report that on May 15, 2017, the Company’s Board of Directors approved the appointment of Mr. Orwin>to the Compensation Committee>of the Board of Directors effective May 17, 2017.
About RETROPHIN, INC. (NASDAQ:RTRX)
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1. RETROPHIN, INC. (NASDAQ:RTRX) Recent Trading Information
RETROPHIN, INC. (NASDAQ:RTRX) closed its last trading session down -0.60 at 17.03 with 197,608 shares trading hands.
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1. RETROPHIN, INC. (NASDAQ:RTRX) Recent Trading Information
RETROPHIN, INC. (NASDAQ:RTRX) closed its last trading session down -0.60 at 17.03 with 197,608 shares trading hands.
